New hope for rare kidney cancers: testing a powerful drug duo
NCT ID NCT06302569
Summary
This study is testing whether a combination of two drugs, pembrolizumab and enfortumab vedotin, can help control two rare and aggressive types of kidney cancer. It will enroll about 23 adults with advanced collecting duct carcinoma or renal medullary carcinoma. The main goal is to see how many patients' tumors shrink or disappear with this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL MEDULLARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Fondazione Irccs Istituto Dei Tumori Di Milano
RECRUITINGMilan, 20133, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.